SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 31477497.
- Also identified by DOI 10.1016/j.cmet.2019.08.015.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hess et al. quantified circulating aldehyde dehydrogenase-expressing (ALDHhi) cell subsets in people with T2DM given either empagliflozin (EMPA) or placebo. EMPA treatment increased circulating pro-angiogenic CD133+ progenitor cells, decreased pro-inflammatory ALDHhi granulocyte precursors, and increased ALDHhi monocytes with M2 polarization. EMPA treatment improved T2DM-associated "regenerative cell depletion" contributing to enhanced vascular health.
Medical subject headings
- Benzhydryl Compounds
- Cardiotonic Agents
- Cardiovascular Diseases
- Coronary Artery Disease
- Diabetes Mellitus, Type 2
- Glucosides
- Myeloid Progenitor Cells
- Sodium-Glucose Transporter 2 Inhibitors